A 52-year-old man with CKD stage 4 (eGFR 22 mL/min/1.73m²) presents for routine follow-up. His serum phosphate is 5.2 mg/dL, calcium 7.8 mg/dL, and PTH 380 pg/mL. Regarding the management of CKD-mineral bone disorder (CKD-MBD), all of the following are evidence-based interventions EXCEPT:

Explanation

## CKD-Mineral Bone Disorder Management Overview **Key Point:** CKD-MBD management focuses on controlling phosphate, calcium, and PTH to prevent secondary hyperparathyroidism and vascular calcification. The three pillars are phosphate control, calcium balance, and PTH suppression. ### Correct Interventions in CKD-MBD | Intervention | Mechanism | Evidence Base | |---|---|---| | Phosphate binders (Ca acetate, sevelamer, lanthanum) | Reduce intestinal phosphate absorption | Reduces serum phosphate, slows progression | | Calcitriol (active vitamin D) | Raises serum calcium, suppresses PTH directly via VDR | Standard therapy in advanced CKD | | Dietary phosphate restriction | Reduces dietary phosphate load | First-line, non-pharmacological | | Cinacalcet (calcimimetic) | Allosteric modulator of CaSR, suppresses PTH | Used when PTH remains elevated despite other measures | ### Why Sodium Polystyrene Sulfonate Is NOT Part of CKD-MBD Management **High-Yield:** Sodium polystyrene sulfonate (SPS) is a **cation exchange resin** used exclusively for **hyperkalemia management**, not for mineral bone disorder. While hyperkalemia may coexist in CKD patients, SPS does not address phosphate, calcium, or PTH control and has no role in CKD-MBD therapy. **Clinical Pearl:** SPS exchanges Na⁺ for K⁺ in the colon. It is contraindicated in post-operative ileus and carries risk of colonic necrosis, especially when combined with sorbitol. It is NOT a mineral-modulating agent. **Warning:** Do not confuse **potassium binders** (patiromer, sodium zirconium cyclosilicate) with phosphate binders. Both may be used in CKD, but they serve different purposes — K⁺ control vs. phosphate control. ### Secondary Hyperparathyroidism Pathophysiology in CKD 1. Declining GFR → reduced 1,25-dihydroxyvitamin D production 2. Hyperphosphatemia (reduced urinary excretion) 3. Hypocalcemia (low calcitriol, high phosphate) 4. PTH secretion increases (compensatory) 5. Chronic stimulation → parathyroid hyperplasia → tertiary hyperparathyroidism **Key Point:** Early intervention with phosphate binders, calcitriol, and dietary counseling can slow or prevent this cascade [cite:KDIGO CKD-MBD 2017]. [cite:Harrison 21e Ch 279]